Annual screening for lung cancer using computed tomography (CT) can help detect the disease at its earliest, most curable stage, but it does not reduce mortality from the disease and could actually result in more harm than good, according to a new study.
A new study provides more evidence that women who are at increased risk of developing breast cancer can significantly reduce their risk by having both breasts removed, a procedure known as bilateral prophylactic mastectomy. The risk reduction in the current study was about 95 percent.
High blood levels of the major vitamin E components, alpha- and gamma-tocopherol, seem to cut the risk of prostate cancer by about 50 percent each, a study shows.
An experimental treatment that harnesses the immune system to attack tumors can extend the lives of men fighting advanced prostate cancer, according to a study released, marking the first time a cancer vaccine has been shown to improve survival for any malignancy.
Virginia scientists say a compound derived from a rare South American plant stops the growth of human breast cancer cells in laboratory cultures.
Vitamin E from seeds, but not most supplements, might halt the growth of prostate and lung cancer cells, scientists at Purdue University reported.
A woman’s risk of developing breast cancer is due in part to a group of very small variations in genes which code for a cell’s estrogen receptors, according to a collaborative study by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, Memorial Sloan-Kettering Cancer Center, Celera Diagnostics, SAIC-Frederick Inc., Applied Biosystems, the Massachusetts Institute of Technology and Vanderbilt University School of Medicine. The study appears in the December 15, 2004, issue of Cancer Research.
A new test can predict both the risk of breast cancer recurrence and may identify women who will benefit most from chemotherapy, according to research supported by the National Cancer Institute (NCI), part of the National Institutes of Health, and performed in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health Inc. These results suggest that almost half of 43,000 U.S. women diagnosed with estrogen-dependent, lymph-node negative breast cancer every year are at low risk for recurrence and may not need to go through the discomfort and side effects of chemotherapy.
Scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, have created a model that predicts the survival of follicular lymphoma patients based on the molecular characteristics of their tumors at diagnosis. The model is based on two sets of genes – called survival-associated signatures – whose activity was found to be associated with good or poor prognosis for patients with the cancer. The scientists’ results, to be published in the November 19, 2004, New England Journal of Medicine, suggest that immune cells infiltrating follicular lymphoma tumors have an important impact on survival – both signatures came from such immune cells.
The most comprehensive federal report available on state-specific cancer rates for the first time includes information on incidence and death rates, as well as data for Hispanics and a new section on mesothelioma and Kaposi’s sarcoma. U.S. Cancer Statistics: 2001 Incidence and Mortality includes quality-assured incidence data from 43 states, six metropolitan areas, and the District of Columbia, covering 92 percent of the U.S. population – up from the coverage rate of 84 percent for the report issued last year. The report supplies essential state, population, racial, ethnic and gender information for tailored cancer prevention and control programs nationwide.